Sarepta Therapeutics Inc.
DMD
Sarepta Therapeutics is the global leader in gene therapy and RNA-targeted therapeutics for rare neuromuscular diseases, generating $1.86 billion in net product revenue during 2025. Its Duchenne muscular dystrophy (DMD) gene therapy ELEVIDYS achieved $899 million in sales, while its PMO-based RNA therapies contributed $966 million. The company's strategic restructuring, including a 36% workforce reduction, has positioned it for sustained cash flow generation.
Strengths: Unique dual-platform approach covering both gene therapy (AAV) and RNA-targeted (PMO) modalities; ELEVIDYS label expansion to broader DMD patient population driving revenue acceleration; global partnership with Roche for ex-US commercialization; deep rare disease expertise with strong patient community relationships; cash reserves exceeding $950 million post-restructuring.
Weaknesses: Significant safety concerns with ELEVIDYS-associated acute liver failure cases leading to FDA black box warning; 36% workforce reduction may impact long-term innovation capacity; high dependency on DMD market with limited pipeline diversification; manufacturing relies on external CDMO partnerships rather than internal capacity.Read MoreShow Less
Strengths: Unique dual-platform approach covering both gene therapy (AAV) and RNA-targeted (PMO) modalities; ELEVIDYS label expansion to broader DMD patient population driving revenue acceleration; global partnership with Roche for ex-US commercialization; deep rare disease expertise with strong patient community relationships; cash reserves exceeding $950 million post-restructuring.
Weaknesses: Significant safety concerns with ELEVIDYS-associated acute liver failure cases leading to FDA black box warning; 36% workforce reduction may impact long-term innovation capacity; high dependency on DMD market with limited pipeline diversification; manufacturing relies on external CDMO partnerships rather than internal capacity.
Listed market data
SRPT · NASDAQ · weeklyHistory →- Market cap
- $1.8 B
- Share price
- USD 17.10
- 1Y change
- -24.0%
- Recent change
- -2.5%
- IPO price
- -58.5%
- Revenue (TTM)
- $2 B
10-22 → 10-23
USD 9.00 · from 6/04/1997
Financial history
Full market history- 2026-10USD 17.10$1.8 B-6.1%
- 2026-09USD 18.22$1.8 B-13.4%
- 2026-08USD 21.03$2.1 B+41.5%
- 2026-07USD 14.86$1.5 B-17.3%
- 2026-06USD 17.97$1.8 B+0.6%
- 2026-05USD 17.87$1.8 B-14.4%
- 2026-04USD 20.88$2.1 B-4.0%
- 2026-03USD 21.76$2.2 B+29.8%
- 2026-02USD 16.76$1.7 B-17.6%
- 2026-01USD 20.34$2.1 B-5.5%
- 2025-12USD 21.52$2.2 B+0.8%
- 2025-11USD 21.34$2.2 B—
In the press
All coverage →5 latest headlines- H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Lobbying Update: $160,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitativewww.quiverquant.com2026-10-20
- Sarepta Therapeutics Inc (AB3A.SG) stock price, news, quote and history - Yahoo Finance UKuk.finance.yahoo.com2026-10-20
- Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwitsstocktwits.com2026-10-17
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meetingfinance.yahoo.com2026-10-14
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $2.2 B | −$713 M |
| 2024 | $1.9 B | $235 M |
| 2023 | $1.2 B | −$536 M |
| 2022 | $933 M | −$703 M |
| 2021 | $702 M | −$419 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Cambridge, Massachusetts, United States
Founded
1980
Employees
835
Revenue
$1.86B (net product revenue, 2025)
Market cap
$1.8 B
Factories
External CDMO network (reliance on top-tier partners)
Presence
US, Japan, select European markets
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Industry rankings
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: SRPT , Sarepta Therapeutics FY2025 Results | Sarepta 2025 SEC 10-K Filing | Sarepta Strategic Restructuring Announcement | Sarepta Employee Data — Stock Analysis